Dashboard
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 7.51 times
- The company has been able to generate a Return on Equity (avg) of 0.90% signifying low profitability per unit of shareholders funds
Flat results in Mar 25
Stock is technically in a Mildly Bearish range
Risky - No result in last 6 months
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Specialty Chemicals
INR 3 Cr (Micro Cap)
NA (Loss Making)
23
0.00%
-0.97
91.44%
-0.13
Total Returns (Price + Dividend) 
Unitech Internat for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
27-May-2026 | Source : BSEDisclosure in pursuance of regulation 30 of the SEBI (LODR) Regulation 2015 read with subclause 16(g) of clause A of Part A of schedule III this is to inform you that 10th meeting of Committee of Creditors of Unitech International Limited was scheduled on 22.05.2026 Friday at 12:00 PM through video conferencing.
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
16-Apr-2026 | Source : BSEDisclosure in pursuance of Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 read with sub-clause 16 (g) of Clause A of Part-A Schedule III to inform you that the 8th meeting of the committee of creditors of Unitech International Limited is scheduled for tomorrow i.e. Friday 17th April 2026 at 4:30 P.M. through video conferencing.
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
25-Mar-2026 | Source : BSEThat the 7th CoC meeting held on 24-03-2026 minutes duly circulated on 25-03-2026. The discussion was made on appointment of legal counsel; appointment of PSC firm; ratification of CIRP expenses; fee approval of accountant; fee approval of statutory auditor and approval of RFRP and EM.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Desai Dhruv Rajesh (24.08%)
Harshil Mayurbhai Shah (4.64%)
60.92%
Quarterly Results Snapshot (Standalone) - Mar'25 - QoQ
QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024
QoQ Growth in quarter ended Mar 2025 is 61.36% vs -109.52% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'24
Growth in half year ended Sep 2024 is -99.79% vs -63.57% in Sep 2023
Growth in half year ended Sep 2024 is 42.51% vs -20.14% in Sep 2023
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is -99.81% vs -70.19% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 23.01% vs 12.77% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -99.80% vs -78.26% in Mar 2024
YoY Growth in year ended Mar 2025 is 90.01% vs -88.40% in Mar 2024